Zum Hauptinhalt springen

Neuropathische Schmerzen

Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:


  • Deutsche Gesellschaft für Neurologie. Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. AWMF-Leitlinie Nr. 030-114. S2k, Stand 2019. www.awmf.org 
  • NVL-Programm von BÄK, KBV, AWMF. Nationale Versorgungsleitlinie Neuropathie bei Diabetes im Erwachsenenalter. AWMF-Leitlinie Nr. nvl-001e. S3, Stand 2016 (abgelaufen). www.awmf.org 
  • Torhild Warncke, spesialist i Nevrologi, dr. med.
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor, dr. med
  1. Deutsche Gesellschaft für Neurologie. Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. AWMF-Leitlinie Nr. 030-114, Klasse S2k, Stand 2019. www.awmf.org  
  2. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, Haanpaa M, Jensen TS, Serra J, Treede RD. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010; 17: 1010-8. pubmed.ncbi.nlm.nih.gov  
  3. Baron R. Pharmakotherapie chronischer neuropathischer Schmerzen. Dtsch Arztebl Int 2016; 113: 616-626. doi:10.3238/arztebl.2016.0616 DOI  
  4. Maier C, Bingel U, Diener HC, (Hrsg.): Schmerzmedizin: interdisziplinäre Diagnose- und Behandlungsstrategien. München: Elsevier, Urban & Fischer 2017.
  5. Cormue PJ, Nairn M, Welsh J, on behaf of the Guideline Development Group. Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008; 337: a2154. www.bmj.com  
  6. International Association for the Study of Pain. IASP Council Adopts Task Force Recommendation for Third Mechanistic Descriptor of Pain. November 2017. www.iasp-pain.org  
  7. Baron R. Diagnostik und Therapie neuropathischer Schmerzen. Dtsch Arztebl CME Kompakt 2009; 1(2): 32a-32j. www.aerzteblatt.de  
  8. Krätz FJ, Schäffer J, Gleiter CH et al. Physiologie und Pathophysiologie des Schmerzes. In: Krätz FJ, Schäffer J (Hrsg.) Anästhesie, Intensivmedizin, Notfallmedizin, Schmerztherapie. Heidelberg: Springer 2008
  9. Finnerup N, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review an meta-analysis. Lancet Neurol 2015. doi:10.1016/S1474-4422(14)70251-0 DOI  
  10. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014; Issue 1. Art: No.: CD007115. doi:10.1002/14651858.CD007115.pub3 DOI  
  11. NVL-Programm von BÄK, KBV, AWMF. Nationale Versorgungsleitlinie Neuropathie bei Diabetes im Erwachsenenalter. AWMF-Leitlinie Nr. nvl-001e, Klasse S3, Stand 2016 (abgelaufen). www.awmf.org  
  12. Anand P, Bley K.. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107: 490-502 PubMed  
  13. Molero Y, Larsson H, D'Onofrio et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 2019; 365: l2147. pmid:31189556. www.ncbi.nlm.nih.gov  
  14. Wiffen PJ, Derry S, Bell RF, Rice AS, Toelle TR, Phillips T. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938. pubmed.ncbi.nlm.nih.gov  
  15. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):CD007076. doi:10.1002/14651858.CD007076.pub3 DOI  
  16. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017; Issue 1: Art. No.: CD007393. doi:10.1002/14651858.CD007393.pub4 DOI  
  17. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-46. PMID: 16209908 PubMed  
  18. Koppel, BS, Brust JC, Fife T et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:1556–1563. PMID: 24778283 PubMed  
  19. Petzke F, Enax-Krumova EK, Häuser W. Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen. Eine systematische Übersichtsarbeit von randomisierten, kontrollierten Studien. Schmerz 2016; 30: 62-88. PMID: 26830780 PubMed  
  20. Nugent SM, Morasco BJ, O'Neil ME et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med 2017; 167: 319-331. PMID: 28806817 PubMed  
  21. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329:253. PMID: 15258006 PubMed  
  22. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68: 515–521 PMID: 17296917 PubMed  
  23. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112:299–306. PMID: 15561385 PubMed  
  24. Nurmikko TJ, Serpell MG, Hoggart B et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20. PMID: 17997224 PubMed  
  25. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4(1):245-59. PMID: 18728714 PubMed  
  26. Serpell M, Ratcliffe S, Hovorka J et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014; 18: 999-1012. PMID: 24420962 PubMed  
  27. Karst M, Salim K, Burstein S et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. J Am Med Ass 2003; 290: 1757– 1762 PMID: 14519710 PubMed  
  28. Selvarajah D, Gandhi R, Emery CJ et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128-30. PMID: 19808912 PubMed  
  29. GW Pharmaceuticals: ClinicalTrials.gov; Stand Juli 2012; letzter Zugriff 21.10.2017 clinicaltrials.gov  
  30. Cannabis auf Rezept? a-t 2017; 48: 91-2 www.arznei-telegramm.de  
  31. Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Physician 2017 Sep; 20(6): E755-E796. pmid:28934780 PubMed  
  32. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2018; Issue 3: Art. No.: CD012182. doi:10.1002/14651858.CD012182.pub2 DOI  
  33. Lima MC, Fregni F. Motor cortex stimulation for chronic pain: systematic review and meta-analysis of the literature. Neurology 2008; 70: 2329-37. pubmed.ncbi.nlm.nih.gov  
  34. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010; 74: 173-6 PubMed  
  35. Ju ZY, Wang K, Cui HS, et al. Acupuncture for neuropathic pain in adults. Cochrane Database Syst Rev 2017 Dec 2. doi:10.1002/14651858.CD012057.pub2 DOI  
  • Thomas M. Heim, Dr. med., Wissenschaftsjournalist, Freiburg
  • Michael Handke, Prof. Dr. med., Facharzt für Innere Medizin, Kardiologie und Intensivmedizin, Freiburg i. Br.